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Many theories mention hypersensitive, promiscuous, outlaw or bypass signalling pathways to explain the acquisition of hormone
independence in prostate cancer. Hormonal escape of prostate tumours is marked by many biological changes, including mucinous
and neuroendocrine differentiation. Since expression of several mucins has been linked to carcinoma tumour progression, we have
characterised the expression of mucins at both RNA and protein levels in an in vivo model of prostate cancer in hormonal escape.
Using PAC120, a xenograft of a human hormone-dependent prostate tumour, and its hormone-independent variants, we analysed
the expression of mucins (MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC6) by immunohistochemistry or reverse transcriptase
(RT)–PCR. While the parental PAC120 tumour was a compact poorly-differentiated tumour of Gleason score 9 (5þ4), hormone-
independent variants displayed mucinous, neuroendocrine-like or mixed histological changes; these changes were stable through
serial transplantations or after testosterone supply. MUC1 mRNA was expressed in both PAC120 and the hormone-independent
variants, although at variable levels. All tumours displayed a high and constant expression of MUC2 and no expression of MUC4
mRNA. While MUC1 was expressed in all xenografts whatever their hormone dependence status, MUC2, MUC5B and MUC6 were
preferentially expressed in hormone-independent variants. The loss of hormone dependence in this prostate cancer xenograft model
is therefore marked by irreversible histological alterations, mucinous or neuro-endocrine, associated with an expression of secretory
MUC2, MUC5B and MUC6, independent of the histological differentiation subtype. These data point to mucinous differentiation as
an important step in the acquisition of hormone independence in this cancer, and suggest that secretory mucins might participate in
an unknown pathway of hormonal escape in prostate cancer.
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Androgen deprivation therapy has been used for decades in the
treatment of prostate cancer (Huggins, 1967). However, although
this treatment is initially very effective in these hormone-
dependent cancers, they invariably become hormone-refractory
and metastasise, leading to the death of patients. Recently,
Feldman and Feldman (2001) reviewed possible mechanisms by
which prostate cancer can escape androgen deprivation therapy.
While the androgen receptor (AR) is activated by testosterone-
induced phosphorylation in hormone-dependent prostate tu-
mours, hormone-independent growth might be due to the
activation of AR via a phosphorylation event induced by other
growth factor receptors, such as HER1 (EGFR) and HER2 (Her2/
neu) (Kwong and Hung, 1998; Yeh et al, 1999). In addition, several
recent studies have linked the IGF-1 receptor pathway to the
stimulation of the androgen-signalling pathway in hormone-
refractory prostate cancer (Culig et al, 1994; Bubendorf et al,
1999). Hormone-independent growth of prostate tumours has also
been associated with biological changes such as mucinous and
neuroendocrine differentiation. Neuroendocrine differentiation
has been observed in prostate cancer and has been correlated
with tumoural aggressiveness, short survival and poor response to
endocrine therapy (McWilliam et al, 1997), and was considered to
be an early marker of progression toward hormone independence
(Cohen et al, 1991; Di sant’Agnese and Cockett, 1996; Noordzij
et al, 1996). Although true mucinous or colloid prostatic
adenocarcinoma, with extensive mucin production, remains a rare
entity (Epstein and Lieberman, 1985; Nagakura et al, 1986),
production of neutral mucin as assessed by immunohistochem-
istry is found in up to 55% of prostate carcinomas (Sentinelli,
1993). A total of 19 different mucin genes (MUC1–MUC4, MUC5B,
MUC5AC, MUC6–MUC18) have been identified to date and
divided into two groups: those coding for membranous mucins
such as MUC1, MUC3 and MUC4, and those coding for secreted
mucins such as MUC2, MUC5AC, MUC5B and MUC6. Secreted
mucins are glycoproteins constituting the major macromolecular
component of mucus, while membrane-associated mucins con-
tribute to epithelial cell–cell interactions. Their pattern of
expression, especially for the secreted mucins, appears to be
relatively tissue-specific. However, the distribution and type of
mucin produced by normal prostatic tissue and prostatic
carcinomas are not well documented (Daher et al, 1990), though
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sfocal mucin production in conventional prostatic adenocarcino-
mas has been recognised for many years (Pinder and McMahon,
1990). Mucin expression has also been observed in a few cases of
prostatic intraepithelial neoplasia (PIN) (Sentinelli, 1993).
MUC1, designated also as the CA19.9 marker, is frequently
expressed in many types of cancer (Chu and Chang, 1999), and was
found to be highly expressed in normal prostatic glandular tissue
and in prostatic adenocarcinoma (Ho et al, 1993). Its detection in
the blood is a good indicator of the presence and burden of the
tumour, but its biological role in cancer is poorly understood. In a
recent study, its expression was detected in 94% of prostate
tumours examined, and the intensity of the cytoplasm staining was
significantly correlated with the tumour grade and stage
(Kirschenbaum et al, 1999). MUC2 is not expressed in any
prostatic tissues (Ho et al, 1993), but in the majority of colon
adenocarcinomas, particularly those of colloid type (Hanski et al,
1997). MUC5AC is highly expressed in normal prostatic glandular
tissue (Daher et al, 1990) and in colon adenocarcinomas (Bara et al,
1991), while MUC4, MUC5B and MUC6 are not expressed in
prostatic glandular tissue.
In this study, we have used a xenograft model of human prostate
cancer to explore the changes in histology and mucin expression
patterns occurring during the progression to hormone indepen-
dence. PAC120 is a human prostate cancer xenograft obtained by
urethral resection of a recurrent prostate cancer, and direct
subcutaneous engraftment into nude mice (de Pinieux et al, 2001).
PAC120 is androgen-responsive, but recurs as hormone-refractory
disease following transplantation in castrated mice. We have
compared the hormone-responsive PAC120 parental tumour with
several independently obtained hormone-refractory tumour var-
iants for their mucinous and neuroendocrine histological compo-
nents, and analysed the relationship between these phenotypic
changes and the expression of mucins at the RNA and protein
levels.
MATERIALS AND METHODS
Prostate tumour xenografts
All the experiments were realised in vivo and have been carried out
with ethical committee approval, and meet the standards required
by the UKCCR guidelines (Workman et al, 1998).
The parental tumour PAC120, a hormone-dependent human
prostate cancer xenograft transplantable into nude mice, was
established in our laboratory (de Pinieux et al, 2001). The original
PAC120 tumour appeared 7 months after grafting, and was
maintained by serial transplantation during several passages
(p4–p29) by subcutaneous implantation of tumour fragments.
The mean delays between two passages were of 5 months. HIDs are
hormone-independent variants that were obtained in nude mice
after surgical castration. PAC120-bearing mice were castrated
when the local tumours reached 250–500mm
3. After a variable
latency, HID tumours started to grow again. Seven HID variants
were independently isolated. The recurrence latencies were 16, 7, 8
months for HID25, HID28, HID33, respectively, and 12 months for
the four later variants HID16, HID19, HID34 and HID35. Delays
before the second passage in precastrated males were between 3
and 6 months. One variant, HID28, was transplanted into both
castrated and uncastrated male mice.
Immunochemical studies
Two PAC120 tumour samples (passages p4 and p20) and the
seven HID tumours were removed from mice and immediately
fixed in a 95% ethanol solution for immunohistological studies
of MUC1, MUC2, MUC5AC (Daher et al, 1990), MUC5B and
MUC6 expression; this fixation is known to protect the integrity
of mucin epitopes. All tumour samples were screened for
mucin production with alcian blue (pH 2.5) and periodic acid
Schiff stains. The antibodies used for immunohistochemical
(IHC) studies, their sources and dilutions are listed in Table 1.
Tissues employed as positive controls are indicated in the
same table.
Standard immunohistochemistry by avidin–biotin complex
(ABC) immunoperoxidase technique was done as follows. Paraf-
fin-embedded sections, 4-mm thick, were used for light microscopy
examination after haematoxylin–eosin–safran (HES) staining,
and for immunohistochemistry. Immunohistochemical study of
MUC1, MUC2, MUC5B, MUC5AC and MUC6 mucin expression
was performed on all tumour samples.
Immunostaining was performed on sections, mounted onto
silane coated slides, air dried, deparaffinised in xylene and
rehydrated. Slides were washed three times in phosphate-buffered
saline (PBS, pH 7.4) between each incubation step of the
procedures. Endogenous peroxidase activity was blocked by
incubation of samples in 0.3% hydrogen peroxide in methanol
for 30min. Tissue slides were microwaved in 0.01 M sodium citrate
buffer (pH 6) near boiling for 20min, and cooled for 30min in the
buffer before incubation with the primary antibodies. Sections
were then incubated with normal serum (1:20 in PBS) for 20min
to block nonspecific serum-binding sites. Primary antibodies were
incubated on tissue sections at room temperature for 1h. After
incubation with a biotinylated secondary antibody, the immuno-
histochemical reaction was visualised using ABC (Vectastain Elite
kit, Vector Laboratories, Burlingame, CA, USA) with the chromo-
gen amino-ethylcarbazol (AEC). Sections were counterstained by
Mayer’s haematein solution. In each case, appropriate positive and
negative controls were tested simultaneously. Staining intensity
was assessed semiquantitatively as 0 (negative), þ(weak to
moderate) and þþ(strong). The pattern distribution of staining
was focal (F) or diffuse (D).
Detection of mRNA transcripts by reverse transcriptase
(RT)–PCR
Xenograft samples were harvested 6–8 weeks after grafting and
snap-frozen in liquid nitrogen for subsequent RNA extraction.
RNA was prepared using a commercially available kit (Trizol,
Invitrogen, Gercy Pontoise, France). RNA quality was confirmed
Table 1 Immunoreagents used in the immunohistochemical analysis
Reagent Source Dilution Positive control
Anti-MUC1 (monoclonal H23) Transgene (Strasbourg, France) 1:100 Breast cancer
Anti-MUC1 (monoclonal M8) A gift from S Gendler (Gendler and Spicer, 1995) 1:10 Gastric mucosa
Anti-MUC2 (polyclonal Lum 2–3) I Carstedt 1:1000 Colonic mucosa
Anti-MUC5B (monoclonal EU1) D Swallow 1:10 Bronchial epithelium
Anti-MUC5B (polyclonal Lum 5B-2) I Carstedt 1:1000
Anti-MUC5AC (monoclonal 21M1) A gift from J Bara (Daher et al, 1990) 1:10 Gastric mucosa
Anti-MUC6 (monoclonal F8) P Real 1:10 Gastric mucosa
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sby gel electrophoresis and ethidium bromide staining, or by RNA
6000 Assay (Agilent Technologies 2100 Bioanalyser, Massy,
France). Reverse transcription of RNA was performed in a final
volume of 20ml containing 5  RT buffer (Invitrogen), 100mM
DTT, 200ngml
 1 oligodT, 2.5mM dNTP and 200unitsl
 1 of
reverse transcriptase. The samples were incubated at 421C for 1h,
and then kept frozen until use. A measure of 100ng of cDNA was
used for each PCR reaction. PCR amplification was performed
using human tubulin-b2 primers as control, and MUC1, MUC2
and MUC4 primers (Table 2). The thermal cycling conditions
comprised 40 cycles at 941C for 1min, 601C for 1min and 721C for
1min.
For real-time RT–PCR, RT of RNA was realised by random
priming (cDNA cycle Kit, Invitrogen). Primers for the MUC1
mRNA were designed with the Primer Express (ABI, Les Ulysses,
France) and ClustalX softwares. We conducted BLASTN searches
to confirm the gene specificity of the nucleotide sequences chosen
(Table 3). To avoid amplification of contaminating genomic DNA,
one of the two primers was placed across a splice junction. QPCR
was performed using the qPCRt Core Kit for Sybrt Green I
(Eurogentec, Seraing, Belgium) to quantify the MUC1 transcripts.
DNAc (50ng) was used for each PCR. The thermal cycling
conditions comprised an initial denaturation step at 951C for
10min and 45 cycles at 951C for 15s and 601C for 1min.
Experiments were performed in triplicate for each data point. We
quantified HPRT transcripts (human hypoxanthine phosphoribo-
syltransferase) as an endogenous RNA control, and each sample
was normalised on the basis of its HPRT content. Biologically
significant variations were defined for genes with a ratio X2.
RESULTS
Histological features of PAC120 and HID tumour
xenografts
The histological features of PAC120 xenografts were those of a
poorly differentiated, Gleason score 9 (5þ4), conventional
prostate adenocarcinoma, without any evidence of mucus
secretion. PAC120 reproduced the morphological and biological
characteristics of the original tumour as published (de Pinieux
et al, 2001), with a compact, lobular pattern and sparse
gland lumens (Figure 1A). During serial transplantation,
PAC120 displayed a very stable morphology and histology
(neither mucinous nor neuroendocrine differentiation were
observed), and remained hormone-dependent for 29 passages
over 7 years.
Castration of tumour-bearing hosts induced tumour growth
arrest, followed by a decrease in tumour size. Tumours recurred
after various prolonged delays, from 7 to 16 months. The recurrent
tumours kept growing upon transplantation into castrated mice,
confirming their hormone independence. Seven hormone-
independent variants (HID) were obtained independently
from PAC120. Compared to the parental hormone-dependent
PAC120 tumour, HIDs displayed distinctive histological
changes typical of advanced prostate cancer, such as mucinous,
neuroendocrine-like or mixed differentiation features. Several
tumours originating from the same variants were studied.
The histological pattern of HID28 (Figure 1B) and HID16 was
close to that of PAC120, with few areas exhibiting a neuroendo-
crine-type pattern (Figure 1C) or mucinous areas. Growth of
HID28 tumours in intact animals did not alter tumour morphol-
ogy, although their growth was accelerated (de Pinieux et al,
2001). HID25 contained principally signet-ring cells (Figure 1D),
while HID33 was mucinous. HID19 consisted of a clear-cut
juxtaposition of areas of compact poorly differentiated
carcinoma and mucinous adenocarcinoma. In HID19, the less-
differentiated tumoural component showed pleiomorphic tumour
cells arranged in large sheets, without glandular differentiation.
HID34 and HID35 tumours exhibited focal areas, with a
morphological pattern associating neuroendocrine-type with
mucinous areas. The histological patterns of these different
tumour variants are summarised in Table 4. Four of the seven
HID variants presented a dominant neuroendocrine differentiation
and five a dominant mucinous phenotype. In all cases, the
mucinous tumours contained signet-ring cells, extracellular mucin
lakes (colloid carcinoma areas) and glandular structures delimited
by a layer of mucin-secreting tumour cells. Intra- and extracellular
mucin stained positively for alcian blue pH 2.5 (Figure 2A) and
periodic acid Schiff.
Immunohistochemical detection of mucins
MUC1 was detected in PAC120 tumours, the anti-MUC1 antibody
staining focally the cytoplasm of 10–20% of tumour cells
(Figure 2B). The anti-MUC2 and anti-MUC5AC antibodies stained
Table 2 Primers used for the study of mucin genes by RT–PCR
Genes Primers 50-30 Position bp GENBANK Accession no
MUC1 S:ACTCTGATACTCCTACCACCCTTG 830–853 406 X52228
AS:CACCCAGAACTGTACCTGAACTTA 1235–1212
MUC2 5:CTGCACCAAGACCGTCCTCATG 15291–15312 401 L21998
AS:GCAAGGACTGAACAAAGACTCAGAC 15667–15699
MUC4 S:CGCGGTGGTGGAGGCGTTCTT 3094–3114 596 AJ24246
AS:GAAGAATCCTGACAGCCTTCA 3670–3690
Tubulin-b2 5:CGAAGCTCTCTACGACATT 669–688 489 NM 006088
AS:GAAGGTGGCGGACATTTTTAG 1139–1158
Table 3 Primers used for the study of MUC1 gene by real-time RT–PCR
Genes Primers 50-30 Position bp GENBANK Accession no
HPRT S: GCTTTCCTTGGTCAGGCAGTATAA 523–546 141 NM 000194
AS: AAGGGCATATCCTACAACAAACTT 641–664
MUC1 S: CTTTCTTCCTGCTGCTGCTCCT 22–44 95 NM 002456
AS: AGCCGAAGTCTCCTTTTCTCCA 96–117
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sthe cytoplasm of very few tumour cells in the compact areas (data
not shown). Anti-MUC5B and anti-MUC6 antibodies did not stain
PAC120 tumours (data not shown). It should be emphasised that
staining of mucins by the selected antibodies was strictly
dependent on the tissue-fixation method, as we used a 95%
ethanol solution, a technical published by one of us (Daher et al,
1990).
In the HID variants, MUC1 was expressed focally with cytoplasm
positivity in HID16, HID19, HID33, or membrane positivity in
HID19, HID25, HID28, and in the neuroendocrine-type tumour
Figure 1 Histology of human prostate cancer after xenografting, PAC120 and HID variants. (A) PAC120, compact with glandular differentiation
(HES 200). (B) HID28, a microscopic pattern similar to that of the PAC120 tumour (HES  200). (C) HID16, focal neuroendocrine-like pattern (HES
 200). (D) HID25, a fully mucoid adenocarcinoma (HES  200).
Table 4 Expression patterns of mucins in xenografts of PAC120 prostate adenocarcinoma and of its HID variants (Immunohistochemistry detection)
Tumours Histological pattern MUC1 MUC2 MUC5AC MUC5B MUC6
PAC120 Compact area ++
a,c +
b,c +
b,c 00
Mixed
d
HID16 Compact area ++
a,c +
b,c 00 0
Neuroendocrine area ++
a,c 00 0 0
Mixed:
HID28 Compact area +
b,e +
b,e 0+
b,e 0
Neuroendocrine area 0 ++
f,g 0+
g ++
g
HID25 Mucinous area +
a,e ++
f,g 0+
g ++
g
HID33 Mucinous area ++
a,c +
b,c 00 0
Mixed:
HID19 Compact area ++
a,c 00 0 0
Mucinous area +
a,e ++
f,g 0+
g ++
g
HID34 Mixed:
HID35 Neuroendocrine area ++
a,c 00 0 0
Mucinous area 0 ++
f,g 0+
g ++
g
Staining intensity: 0: negative; +: low to moderate; ++: strong. Immunostaining:
afocal;
bon rare cells;
ccytoplasmic;
dtumour samples exhibiting different patterns of differentiation
with or without testosterone support;
emembranous;
fsignet-ring cells;
gextracellular mucin lakes.
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sfoci of HID16, HID34 and HID35. MUC1 immunoreactivity was
observed at the apex of occasional tumour cells delimiting
mucosecreting glandular tubes in HID25 (Figure 2C) and in
HID19 tumours. MUC1 and MUC2 mucins were not simulta-
neously expressed in tumour cells. Anti-MUC2 antibodies stained
rare tumour cells in PAC120 p4 (Figure 2D) and in HID16
(Figure 2E), HID28 and HID33, while signet-ring cells were
uniformly stained in HID25 (Figure 2F) and in the other HID
variants. Extracellular mucin lakes were strongly stained by
the anti-MUC2 and anti-MUC6 antibodies (Figure 2G), and weakly
Figure 2 Expression patterns of different mucins in xenografts PAC120 and HID variants by immunohistochemistry. (A) Alcian blue pH 2.5 in HID-19:
signet-ring cells staining positively (HES  400) (B) MUC1 expression in PAC120: cytoplasmic immunostaining in a fraction of the tumour cells (HES
 400). (C) MUC1 expression in HID25: scattered tumour cells staining positively for MUC1 with a cytoplasmic pattern (HES  400). (D) MUC2
expression in PAC120 p4: rare tumour cells exhibiting cytoplasmic staining (HES  400). (E) MUC2 expression in HID16: rare tumour cells exhibiting
cytoplasmic staining (HES  100). (F) MUC2 expression in HID25: uniform and strong intracytoplasmic positivity of signet-ring cells (HES  100). (G)
MUC6 expression in HID35, mucinous areas: strong staining of extracellular mucin lakes (HES  100). (H) MUC5B expression in HID19, mucinous areas:
strong staining of extra cellular mucin lakes (HES  100).
Mucins in hormone-independent prostate cancer
M-E Legrier et al
724
British Journal of Cancer (2004) 90(3), 720–727 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sby the anti-MUC5B antibodies (Figure 2H). MUC5AC mucin
was not expressed in the HID xenografts. There was no significant
modification in mucin expression between HID28 tumours
with or without testosterone supply. Colorectal mucosa was used
as positive controls for MUC2, gastric mucosa for MUC1,
MUC5AC, MUC6 and bronchial mucosa for MUC5B (Table 1).
MUC2 was not detected in normal prostate tissue, except in
cells derived from the duct utriculum (data not shown).
The immunohistochemical localisation of different mucins is
reported in Table 4.
Evaluation of mRNA transcript levels by RT–PCR
Evaluation of the expression of the mucin genes at the RNA level
was done in the same samples that were used for immunohis-
tochemistry, and in samples derived from successive transplanta-
tions. Expression of the different mucins was investigated by
semiquantitative RT–PCR using oligonucleotides specific for
human MUC1, MUC2 and MUC4 (Figure 3A). Expression of
tubulin-b2 was used as endogenous control. The MUC1 transcript
was detected at low levels in HID16, HID19, HID33 and HID35 and
at higher levels in the other variants, while MUC2 was expressed at
high levels in PAC120 and in all HID variants. No MUC4
expression was detected, while a small-cell lung tumour (SCLC-
6) used as control was positive. MUC1 mRNA expression was also
assessed by real-time RT–PCR, using HPRT as the reference gene
against which MUC1 mRNA levels were normalised (Figure 3B).
Again, MUC1 expression was moderate to high in hormone-
dependent xenografts, and variable in hormone-independent
prostate xenografts, according to the semiquantitative RT–PCR
results. Analysis of real-time PCR data showed that MUC1
expression decreased when HID28 grew in intact animals, that is,
with testosterone support.
DISCUSSION
Tumour escape from hormone deprivation therapy is a major
obstacle in the clinical management of prostate cancer. However,
the biological basis of the acquisition of hormone independence by
these tumours is still poorly understood. This is in part due to the
difficulty in obtaining clinical samples at the various stages of
prostate tumour progression, and also to the fact that only a few
experimental systems are amenable to the study of prostate cancer
hormonal escape (Nagabhushan et al, 1996).
PAC120 is a hormone-dependent poorly differentiated prostate
adenocarcinoma xenograft that displayed no major morphological
changes along successive transplantations (passages p4–p29), and
from which several distinct HID variants have been obtained in
vivo (de Pinieux et al, 2001). It is noteworthy that the hormone-
dependent phenotype of PAC120 was consistently maintained for 7
years. Morphological changes appeared as a consequence of
hormonal escape after surgical castration. HID tumour variants
presented three different phenotypes: neuroendocrine, mucinous
or mixed. The neuroendocrine type was characterised by tumour
cells arranged in large tumoural cords intermingled in a
conjunctiva-vascular stroma. The mucinous differentiation associ-
ates glandular structures delimited by a layer of mucin-secreting
normal 
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Figure 3 RT–PCR analysis of mucin genes expression in PAC120 and HID variants. (A) mRNA transcripts of human MUC1, MUC2 and tubulin-b2 genes
by RT–PCR. mRNA was extracted from hormone-dependent and -independent tumours. Products of RT–PCR of PAC120, HID variants and normal
prostate tissue were deposited successively. (B) Expression of MUC1 transcripts by real-time PCR into the different samples, compared to HPRT gene.
Products of RT–PCR of PAC120 and HID variants were deposited successively.
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stumour cells, extracellular mucin lakes and independent signet-
ring cells. In HID variants, the neuroendocrine tumours presenting
a variable contingent of neuroendocrine areas (four out of seven)
and the mucinous variants (five out of seven) were frequent and
stable during successive passages. Some variants presented as
poorly differentiated adenocarcinomas, as observed in the parental
PAC120 tumour.
The significance of these morphological changes remains
unknown, though they must be somehow related to tissue suffering
and survival as a consequence of hormone deprivation. Neuroen-
docrine and mucinous differentiation appeared in almost all HID
variants, with a predominance of one phenotype but frequently
mixed, as if a superior degree of tumour heterogeneity was reached
by HID in the course of hormonal escape. In the present study, we
focused on the analysis of the changes in the mucin expression
pattern associated with the acquisition of hormone independence.
Mucinous differentiation in adenocarcinomas is recognised as
characteristic of advanced tumoural stage, especially in prostate
and breast cancers. Production of focal mucus, detected by
histochemistry, was observed in 43–61% of prostatic adenocarci-
nomas (Ro et al, 1988; Pinder and McMahon, 1990). A true
mucinous differentiation, involving more than 50% of tumour
cells, is rare and is a marker of poor prognosis (Pinder and
McMahon, 1990). In colon and breast adenocarcinomas, expres-
sion of mucins was also associated with a low survival rate
(Nakamori et al, 1994; McGuckin et al, 1995). Mucin expression
may contribute to cancer cell survival during tumour progression
and hypoxic conditions found at advanced tumour stages.
Although mucinous differentiation has been observed in patients
with advanced stage prostate cancer (Ro et al, 1988; Pinder and
McMahon, 1990), this was the first observation of such changes
being directly related to hormone deprivation and the acquisition
of hormone independence.
Human mucin genes constitute a family of 19 glycoproteins,
which can be divided into two groups: membrane-bound mucins
(MUC1, MUC3 and MUC4) and secreted mucins (MUC2,
MUC5AC, MUC5B and MUC6). The expression profile of mucins
differs according to the glandular tissue type. Mucins are encoded
by genes located on distinct chromosomes; MUC1, MUC3, MUC4,
MUC7, MUC8 are located on chromosome 1, 7, 3, 4, 12,
respectively, while MUC2, MUC5AC, MUC5B, MUC6 are clustered
in chromosome 11p15. Expression of membrane-bound mucins
MUC1 and MUC4 was analysed in our model. MUC1 mRNA was
detected in PAC120 xenografts, although at variable levels and
regardless of the morphological pattern. By immunohistochem-
istry, the expression profile of MUC1 in the hormone-independent
poorly differentiated, neuroendocrine and mucosecreting subtypes
was similar to that of hormone-dependent tumours. A focal and
intracytoplasmic MUC1 immunostaining was observed in 10–20%
of tumour cells. There was no quantitative relationship between
the MUC1 mRNA and protein expression level. A hypothesis was
that HID cells displayed an adaptation to the environmental
conditions, which implicated the activation of some genes
necessary to their survival during hormonal escape. MUC1
expression was found in most adenocarcinomas of the breast,
lung, stomach, pancreas, prostate and ovary (Ho et al, 1993), and a
diffuse cytoplasm MUC1 immunostaining was associated with a
high Gleason score (Kirschenbaum et al, 1999). MUC4 mRNA,
which was expressed in various epithelial tissues, was not
expressed in PAC120. MUC4 was expressed particularly in lung
carcinomas (Copin et al, 2001) and, interestingly, it was proposed
as a ligand for HER2 (Moniaux et al, 1999; Carraway et al, 2002), a
growth factor receptor of the tyrosine kinase family, putatively
implicated in hormonal escape of breast and prostate cancers.
Thus, in the present study, these membrane-bound mucins do not
seem to be involved in the acquisition of hormone independence,
since MUC4 was not expressed and MUC1 expression was not
associated with any particular morphological pattern.
Actually, the biological role of MUC1 is unclear. It was
suggested that MUC1, a mucin detected in an important
proportion of prostate cancers (Kirschenbaum et al, 1999),
was associated with a decrease of cell to cell (Ligtenberg et al,
1992) or cell to extracellular matrix (van de Wiel-van Kemenade
et al, 1993; Wesseling et al, 1996) interactions, by masking
cellular adhesion molecules. In addition, the cytoplasmic
domain of MUC1 is involved in signalling pathways through
its interaction with b-catenin (Li et al, 1998; Carraway et al,
2002), this interaction being dependent on their phosphorylation
by the glycogen synthase kinase 3b (GSK3b) (Li et al, 1998;
Pignatelli, 1998; Lickert et al, 2000). The variations of phosphor-
ylation might induce variations of b-catenin affinity for its
substrates and therefore its nuclear transfer. b-catenin significantly
enhances androgen-stimulated transcriptional activation by the
AR. The coimmunoprecipitation of b-catenin with AR from
LnCaP cells showed that the two molecules are present in the
same complex, this binding being dependent on androgen (Truica
et al, 2000).
Regarding secreted mucins, MUC2 epitopes were not expressed
in normal prostatic tissue (Ho et al, 1993) except near the
utriculum, but were expressed in prostate cancer. Although
the mRNA of MUC2 was expressed at constant levels in PAC120
and HID tumours, a variable expression of the MUC2 protein
was observed. While only a few tumour cells of PAC120 expressed
MUC2, the HID variants contained much more cells staining
positive for MUC2. Such a discrepancy between mRNA and
protein levels suggests that MUC2 expression is subject to
differential post-transcriptional regulation in hormone-dependent
(HD) and HID tumours. The mucosecreting tumoural subtypes
presented a completely different pattern of mucin expression,
including a high and predominant MUC2 expression. MUC2
expression was characterised by both an intracellular accumula-
tion in signet-ring cells and an extracellular localisation in
mucin lakes. This profile was similar to that of mucinous or
colloid mucinous adenocarcinomas observed in advanced
cancers of various origins, such as the gastrointestinal tract,
ovary or breast (Hanski et al, 1997). This observation suggests
that acquisition by tumour cells of a mucinous phenotype
belongs to a pathway of hormonal escape in prostate cancer.
Mucosecreting cells positive for MUC5AC were present in the
Cowper’s glands and prostatic urethral epithelium near the
utriculum (Daher et al, 1990). Anti-MUC5AC antibodies stained
the cytoplasm of rare cells in PAC120 and did not stain HID
variants. MUC5B and MUC6 were detected in the mucin lakes of
mucinous differentiated variants. So, these secreted mucins were
independently secreted and expressed in a cell type-specific
manner. Overall, MUC2, MUC5B and MUC6 were associated with
mucinous morphology, and were expressed in HID prostate
tumour variants. These three mucins are encoded by genes
colocated in the chromosome 11p15. Their de novo expression
seemed to be concomitant, suggesting either an amplification of
this region or a deregulated expression, which lends further
support to the possibility that these mucins are involved in
hormonal escape. Mucin secretion may affect interactions with the
extracellular environment, which could directly or indirectly
influence proliferation and/or apoptosis of prostate cancer cells.
Additionally, secreted mucins may directly affect tumour cell
behaviour through interactions with membrane components.
Indeed, a recent study revealed the role of MUC5AC, MUC1 and
proteoglycans in the inhibition of E-cadherin function associated
with invasiveness of HT-29 colon adenocarcinoma cell variants
(Truant et al, 2003). We are currently investigating the link
between the expression of secreted mucins, E-cadherin function
and perturbations of the androgen receptor signalling pathway in
hormone-independent prostate tumours.
In conclusion, the loss of hormone dependence in this
prostate cancer xenograft model is marked by irreversible
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are associated with a constant increase in the expression of
secretory MUC2, MUC5B and MUC6, which might participate
in an unknown pathway of hormone escape in prostate cancer.
These data point to mucinous differentiation as an important
step in the acquisition of hormone independence in prostate
cancer.
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